Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia
Public ClinicalTrials.gov record NCT05728944. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Double-Masked Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia
Study identification
- NCT ID
- NCT05728944
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- LENZ Therapeutics, Inc
- Other
- Enrollment
- 229 participants
Conditions and interventions
Conditions
Interventions
- Aceclidine+Brimonidine combination ophthalmic solution Drug
- Aceclidine ophthalmic solution Drug
- Vehicle Drug
Drug
Eligibility (public fields only)
- Age range
- 45 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 5, 2023
- Primary completion
- Dec 13, 2023
- Completion
- Jan 23, 2024
- Last update posted
- Feb 24, 2026
2023 – 2024
United States locations
- U.S. sites
- 17
- U.S. states
- 15
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site #209 | Dothan | Alabama | 36301 | — |
| Site #216 | Scottsdale | Arizona | 85260 | — |
| Site #220 | Glendale | California | 91204 | — |
| Site #214 | La Jolla | California | 92037 | — |
| Site #203 | Newport Beach | California | 92663 | — |
| Site #204 | Danbury | Connecticut | 06810 | — |
| Site #205 | Crystal River | Florida | 34429 | — |
| Site #218 | Northbrook | Illinois | 60062 | — |
| Site #211 | Louisville | Kentucky | 40206 | — |
| Site #208 | St Louis | Missouri | 63128 | — |
| Site #215 | Bozeman | Montana | 59718 | — |
| Site #219 | Dover | New Jersey | 07801 | — |
| Site #221 | Rochester | New York | 14626 | — |
| Site #212 | West Fargo | North Dakota | 58078 | — |
| Site #207 | Powell | Ohio | 43065 | — |
| Site #213 | Eugene | Oregon | 97401 | — |
| Site #217 | Warwick | Rhode Island | 02888 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05728944, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 24, 2026 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05728944 live on ClinicalTrials.gov.